Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab versus placebo in severe uncontrolled eosinophilic asthma
NL-OMON50740Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Benralizumab with Placebo (2 arms). Primary endpoints: Annualized rate of asthma exacerbations, Number of reductions in asthma controller medications and 4 more. Started Mar 2018; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON50740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50740.